Biotech

Biotech catch-all — only use if no sub-Sector applies. Editors should pick a sub-Sector first; only fall back to this term when nothing more specific fits. Mirrors the catch-all pattern on the Datatech, Fintech and Disrupts brands.
Pharmaceuticals
Biotech

Tilray Brands posts record Q1 revenue of $257m, up 23% year-on-year

Tilray Brands reported record first-quarter net revenue of $257m, driven by beverage growth and EMEA expansion, while reaffirming its fiscal 2027 adjusted EBITDA
Tilray Brands reported record first-quarter net revenue of $257m, driven by beverage growth and EMEA expansion, while reaffirming its fiscal 2027 adjusted EBITDA
The Biotech Times Editorial Team  · 
Medical Devices
Digital Health
Biotech

Al Ghurair launches Trellis Health hospital network in Dubai

The UAE conglomerate's new healthcare group opens a 50-bed multi-speciality hospital in Umm Suqeim, with two further clinics due by end of
The UAE conglomerate's new healthcare group opens a 50-bed multi-speciality hospital in Umm Suqeim, with two further clinics due by end of
The Biotech Times Editorial Team  · 
Biotech
Diagnostics
Bioinformatics

Holobiome and Radicle Science launch 6,000-person gut-brain trial

The ARPA-H-backed GUT-FEELINGS study will test 19 prebiotic formulas against anxiety outcomes across 6,000 participants, with initial results expected in late
The ARPA-H-backed GUT-FEELINGS study will test 19 prebiotic formulas against anxiety outcomes across 6,000 participants, with initial results expected in late
The Biotech Times Editorial Team  · 
Biotech
Bioinformatics

Bexorg wins up to $28.3m ARPA-H award to extend human brain perfusion

The New Haven CNS platform company will use the 36-month grant to push its BrainEx system from 24-hour to two-week intact human
The New Haven CNS platform company will use the 36-month grant to push its BrainEx system from 24-hour to two-week intact human
The Biotech Times Editorial Team  · 
Pharmaceuticals
Biotech

Addex Therapeutics posts H1 2026 loss as cash falls to CHF 0.8m

Addex reported a net loss of CHF 3.5m for the first half of 2026, with cash at CHF 0.8m after an ATM raise
Addex reported a net loss of CHF 3.5m for the first half of 2026, with cash at CHF 0.8m after an ATM raise
The Biotech Times Editorial Team  · 
Biotech

Patient safety checklist marks 25 years with reform agenda unfinished

Dr Peter Pronovost's ICU infection checklist turns 25, but patient harm rates in US hospitals have barely shifted in a generation.
Dr Peter Pronovost's ICU infection checklist turns 25, but patient harm rates in US hospitals have barely shifted in a generation.
The Biotech Times Editorial Team  · 
Medical Devices
Biotech

BioStem Technologies secures $40m committed equity facility with Roth

The Nasdaq-listed perinatal tissue allograft maker has agreed a $40 million at-will equity facility with Roth Principal Investments for working capital purposes.
The Nasdaq-listed perinatal tissue allograft maker has agreed a $40 million at-will equity facility with Roth Principal Investments for working capital purposes.
The Biotech Times Editorial Team  · 
Biotech
Bioinformatics

Anew Labs raises $290m at $1.5bn valuation for AI drug discovery

ByteDance's AI drug discovery spin-off Anew Labs has closed a reported $290m first external round, led by HSG, IDG Capital and Hillhouse Investment.
ByteDance's AI drug discovery spin-off Anew Labs has closed a reported $290m first external round, led by HSG, IDG Capital and Hillhouse Investment.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Biotech

RWB acquires controlling stake in European cannabis platform

Red White & Bloom has entered Germany and the UK via a deal giving it majority control of an integrated medical cannabis platform dispensing over 12
Red White & Bloom has entered Germany and the UK via a deal giving it majority control of an integrated medical cannabis platform dispensing over 12
The Biotech Times Editorial Team  · 
Biotech
Bioprocessing

Cannara Biotech expands credit facility to C$80m with BMO and TD

The Québec cannabis producer has upsized its syndicated debt facility by C$30m and extended its maturity to December 2029.
The Québec cannabis producer has upsized its syndicated debt facility by C$30m and extended its maturity to December 2029.
The Biotech Times Editorial Team  · 
Biotech

SGU and Taaleem open medical school pathways for UAE students

St. George's University and UAE school group Taaleem have signed an MoU giving eligible students access to MD admissions pathways and up to USD
St. George's University and UAE school group Taaleem have signed an MoU giving eligible students access to MD admissions pathways and up to USD
The Biotech Times Editorial Team  · 
Medical Devices
Diagnostics
Biotech

Magrabi Health earns first global SRC Network of Excellence in

The Saudi-founded eye care group becomes the first healthcare network worldwide to receive the Surgical Review Corporation's specialist ophthalmology network
The Saudi-founded eye care group becomes the first healthcare network worldwide to receive the Surgical Review Corporation's specialist ophthalmology network
The Biotech Times Editorial Team  · 
Biologics
Biotech

Eascra Biotech wins $7.96m NASA contract for space-made nanomedicine

The Worcester, MA startup will use microgravity manufacturing to advance its RNA-delivery nanoparticle platform toward FDA clinical trials by 2028.
The Worcester, MA startup will use microgravity manufacturing to advance its RNA-delivery nanoparticle platform toward FDA clinical trials by 2028.
The Biotech Times Editorial Team  · 
Digital Health
Biotech

Big Digital Energy signs LOI for 17 MW AI campus in Texas

Big Digital Energy's joint venture has signed a non-binding letter of intent with Tensor IQ to develop a 17 MW AI and HPC
Big Digital Energy's joint venture has signed a non-binding letter of intent with Tensor IQ to develop a 17 MW AI and HPC
The Biotech Times Editorial Team  · 
Biotech

Taranis Capital, Fintech Times & Co-Labs Global Partner on DeepTech

Taranis Capital, The Fintech Times and Co-Labs Global have partnered to accelerate FinTech, AI, RegTech and BioTech growth through capital, media and collaboration.

Strategic collaboration combines capital, media reach and collaborative services to cut through market noise and enable faster, safer and more resilient innovation for those who need it most.

Taranis Capital, Fintech Times & Co-Labs Global Partner on DeepTech  · 
Biotech

UK robotics hits $258M in 2026 YTD funding; Cambridge leads all-time

Tracxn data show UK consumer robotics attracted $258M year-to-date in 2026, with Cambridge accounting for nearly 60% of all-time funding at $1
Tracxn data show UK consumer robotics attracted $258M year-to-date in 2026, with Cambridge accounting for nearly 60% of all-time funding at $1
The Biotech Times Editorial Team  · 
Biotech
Digital Health
Bioinformatics

UK AI funding hits $9.6bn in H1 2026, up 360% year on year

Tracxn data shows five companies absorbed 84% of capital raised, with London capturing 98% of the national total.
Tracxn data shows five companies absorbed 84% of capital raised, with London capturing 98% of the national total.
The Biotech Times Editorial Team  · 
Diagnostics
Digital Health
Biotech

Sigrid Therapeutics lists SiPore® range on Fullscript platform

The Stockholm-based company's gut-local metabolic health products are now accessible to more than 125,000 US practitioners via Fullscript.
The Stockholm-based company's gut-local metabolic health products are now accessible to more than 125,000 US practitioners via Fullscript.
The Biotech Times Editorial Team  · 
Biotech

Eos Energy posts 351% revenue jump but narrows 2026 guidance

The zinc-based storage company grew Q2 revenue to $68.8m but tightened its full-year outlook to $300m–$350m as manufacturing consolidation weighs on
The zinc-based storage company grew Q2 revenue to $68.8m but tightened its full-year outlook to $300m–$350m as manufacturing consolidation weighs on
The Biotech Times Editorial Team  · 
Biotech

Clearmind reports clean CMND-100 safety data across dose escalation

Clearmind Medicine completed all four ascending-dose cohorts of its Phase I/II AUD trial with no serious adverse events recorded.
Clearmind Medicine completed all four ascending-dose cohorts of its Phase I/II AUD trial with no serious adverse events recorded.
The Biotech Times Editorial Team  · 
Subscribe to Biotech